Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 3/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676382 | 0.93 | PDE1B (0.48) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL680616 | 0.84 | PDE1B (0.44) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL680327 | 0.80 | SMN1; SMN2 (0.39) | PDE1BPDE2APDE4DPDE1APDE1C | |
| SCHEMBL675988 | 0.80 | DPP4 (0.38) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL680017 | 0.80 | PDE1B (0.41) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL676380 | 0.76 | PDE1B (0.49) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL17507917 | 0.76 | PDE2A (0.42) | PDE1BPDE2APDE4DGRM2 | |
| SCHEMBL676398 | 0.73 | PTGS2 (0.46) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL26233338 | 0.71 | PDE1B (0.77) | PDE1BPDE2APDE4DGRM2PDE1A | |
| SCHEMBL17507918 | 0.69 | PDE1B (0.66) | PDE1BPDE2APDE4DPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PDE1B 4855/4885PDE2A 1471/4885PDE4D 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.